# Combogesic USA > Generated by All in One SEO Pro v5.0.3, this is an llms-full.txt file, used by LLMs to index the site. ## Pages ### [Home](https://combogesic.com/) **Published:** March 23, 2026 **Author:** damien **Content:** ## Combogesic® is a prescription strength combination of: ### Acetaminophen ### Ibuprofen ## **Non-opioid** pain relief ![](https://combogesic.com/wp-content/uploads/2026/05/GettyImages-1193050201_centered.png) ## Giving your patients the relief they need. **Fast.** ## Delivering superior relief for mild to moderate acute pain compared with acetaminophen or ibuprofen alone.1,2\* [Learn how it works](/why-combogesic/#howitworks) ## Combogesic® tablets ![](https://combogesic.com/wp-content/uploads/2026/05/Combogesic_bottle_NoTopset_no_tablets_clearcut_With_Shadows_New_resized.png) ![](https://combogesic.com/wp-content/uploads/2026/05/tempIcon.png)### 78% ### More effective **pain relief than acetaminophen alone (P<0.001)2** ![](https://combogesic.com/wp-content/uploads/2026/05/tempIcon.png)### 36% ### More effective **pain relief than ibuprofen alone (P<0.001)2** \*Self-reported pain intensity scores were recorded over a 48-hour double blind treatment period using a 100mm visual analogue scale. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over a 48-hour period (SPID48). [See efficacy data](/clinical-overview/#efficacy) ![](https://combogesic.com/wp-content/uploads/2026/06/Powered_by_QikSolv.png) QikSolv™ is a patented breakthrough formulation for rapid dissolution, developed in the US.3 ### Have questions about Combogesic®? Explore frequently asked questions. [FAQ’s](https://combogesic.com/faqs/) ### The clinical data behind Combogesic®. Learn about the clinical evidence supporting Combogesic®. [See Clinical Overview](https://combogesic.com/clinical-overview/) ![](https://combogesic.com/wp-content/uploads/2026/05/GettyImages-1193050201.jpg)## Get in touch [Access Combogesic](/how-to-access/) [Contact Us](https://combogesic.com/contact-us/) Enter your email to receive future updates about Combogesic®. Please enable JavaScript in your browser to complete this form. Email Email \* Submit![Loading](https://combogesic.com/wp-content/plugins/wpforms/assets/images/submit-spin.svg) --- ### [Patients](https://combogesic.com/patients/) **Published:** May 29, 2026 **Author:** damien **Content:** ## Combogesic® is a prescription strength combination of: ### Acetaminophen ### Ibuprofen ## **Non-opioid** pain relief ![](https://combogesic.com/wp-content/uploads/2026/05/GettyImages-1193050201_centered.png) ## Giving you the relief you need. **Fast.** ## Combogesic® is a unique prescription combination of acetaminophen and ibuprofen in a single tablet. ![](https://combogesic.com/wp-content/uploads/2026/05/combogesic_logo_footer.png)### Acetaminophen ### Ibuprofen ![](https://combogesic.com/wp-content/uploads/2026/06/Powered_by_QikSolv.png) QikSolv™ is a patented breakthrough formulation developed in the US for rapid dissolution.3 ![](https://combogesic.com/wp-content/uploads/2026/05/Combogesic_bottle_NoTopset_no_tablets_clearcut_With_Shadows_New_resized.png) ![](https://combogesic.com/wp-content/uploads/2026/05/tempIcon.png)### 78% ### More effective **pain relief than acetaminophen alone (P<0.001)2** ![](https://combogesic.com/wp-content/uploads/2026/05/tempIcon.png)### 36% ### More effective **pain relief than ibuprofen alone (P<0.001)2** \*Self-reported pain intensity scores were recorded over a 48-hour double blind treatment period using a 100mm visual analogue scale. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over a 48-hour period (SPID48). ## Safety ### Combogesic® is non-opioid. Non-addictive. Just relief. Combogesic® tablets minimized the need for opioid analgesia by delaying the time to first request, reducing the overall consumption, and limiting the number of patients who required opioid rescue medication.2 [View study](https://combogesic.com/patients/resources/) ## Why Combogesic®? ### It delivers superior relief for mild to moderate pain compared with acetaminophen or ibuprofen alone. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_more_effective.png) #### More effective Significantly more effective pain relief than either acetaminophen or ibuprofen alone.2 [View study](https://combogesic.com/patients/resources/) ![](https://combogesic.com/wp-content/uploads/2026/06/icon_prolonged.png) #### Works faster Faster onset of meaningful pain relief than acetaminophen or ibuprofen alone.2 [View study](https://combogesic.com/patients/resources/) ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png) #### Non-addictive forming Reduced need for opioid rescue medication.2 [View study](https://combogesic.com/patients/resources/) ## FAQs for Combogesic® tablets ### What are Combogesic® tablets?+ Combogesic® tablets contain a fixed-dose combination of 325 mg acetaminophen and 97.5 mg ibuprofen per tablet. These two active ingredients work via distinct yet complementary mechanisms to provide more effective pain relief than each individual active alone.2 Combogesic® offers a valuable option for the short-term management of mild to moderate acute pain in adults, with several key benefits. These include enhanced analgesic efficacy due to a synergistic action, simplified dosing through the combination of two agents in a single formulation, a well-established safety profile, and the potential to reduce reliance on opioids compared to monotherapy. ### How should Combogesic® tablets be taken?+ Combogesic® tablets are approved for adults only (18 years and above). The dosing regimen is 3 tablets every 6 hours as needed for pain relief, up to a maximum of 12 tablets per day. Combogesic® tablets should be taken at the lowest effective dosage for the shortest duration, consistent with individual patient treatment goals, and should not be administered with other acetaminophen or NSAID-containing products. ### Are there any circumstances in which Combogesic® tablets should not be taken?+ Combogesic® tablets are contraindicated in: - Patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product. - Patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. - The setting of coronary artery bypass graft (CABG) surgery Warning / Precaution is advised in those patients with: - Hypertension - Heart Failure and Edema - Renal Toxicity - Anaphylactic Reactions - Exacerbation of Asthma Related to Aspirin Sensitivity - Serious Skin Reactions - Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) - Fetal Toxicity - Hematologic Toxicity To find the full list of warning and contraindications please see full Prescribing Information including the boxed warning. ### Are Combogesic® tablets safe to take?+ Combogesic® is supported by a robust body of clinical data demonstrating its favorable safety profile. The postoperative safety profile of Combogesic® is comparable to that of acetaminophen and ibuprofen when used individually. By combining two active ingredients, Combogesic® enables the use of a lower dose of the NSAID component, thereby reducing the risk of adverse events typically associated with higher NSAID dosages or the use of more potent NSAIDs. Overall, Combogesic® is well tolerated and demonstrates a strong safety profile when administered as both single and multiple doses. ### What types of pain are Combogesic® tablets suited to treat?+ Combogesic® tablets are intended for adults who need short-term relief of mild to moderate acute pain. They combine acetaminophen and ibuprofen, two active ingredients that work in different ways, providing more effective pain relief than either medicine alone.2 Healthcare professionals may recommend Combogesic® for: - Common acute pain conditions. - Situations where a non-opioid option is preferred to reduce risks of dependence or certain adverse effects. - Patients who benefit from a multimodal approach, taking advantage of both medications together for consistent and reliable pain control. The dosing allows patients to manage pain effectively while staying within dosing limits for acetaminophen and ibuprofen. Its patented formulation is designed for consistent, dependable relief, offering an advantage over taking the two medicines separately. ### Have questions about Combogesic®? [Contact us](https://combogesic.com/patients/contact-us/) [View resources](https://combogesic.com/patients/resources/) --- ### [How to access Combogesic](https://combogesic.com/how-to-access/) **Published:** September 2, 2026 **Author:** damien **Content:** ### Access # How to access Combogesic® ## Request samples Enter your details here and we can reach out to you. [Request samples](https://combogesic.com/hcp-qr/) ## Combogesic® retailers Combogesic can be found at the following retailers. [![](https://combogesic.com/wp-content/uploads/2026/06/Cost-Plus-Drugs-Marketplace-Logo.png)](https://www.costplusdrugs.com/)[Shop on CostPlus](https://www.costplusdrugs.com/) ## How to prescribe Combogesic® is available in your e-prescribing network. **Combogesic® is available in packs of 60 tablets. This covers 5 days’ worth of pain relief when taken at maximum dose.\*** ![](https://combogesic.com/wp-content/uploads/2026/05/Combogesic_bottle_NoTopset_no_tablets_clearcut_With_Shadows_New_resized.png)60 TABLET BOTTLE Product Pack 60 Tablet Bottle NDC Number 72260-129-02 Strength 325 mg acetaminophen + 97.5 mg ibuprofen per tablet Individual Dose **3 tablets every 6 hours** Daily Dose **Up to 12 tablets** Supply Up to 5 days Insurance No insurance required \*Combogesic® should be used with the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Do not administer with other acetaminophen-containing products. #### Questions about access or fulfillment? [Prescribing Information](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf) [Contact a rep](https://combogesic.com/contact-us/) --- ### [How to access Combogesic](https://combogesic.com/patients/how-to-access/) **Published:** September 2, 2026 **Author:** damien **Content:** ### Access # How to access Combogesic® Combogesic® requires a prescription. Ask your doctor about it today by name and explore access options below. ### Already have your prescription? ### Find Combogesic® at the following retailers. #### CostPlus Drugs Transparent cash pricing with home delivery. Send your prescription and order online. [Visit CostPlus Drugs](https://www.costplusdrugs.com/) Retailer links are provided for convenience. Pricing and availability are set by each retailer. --- ### [HCP Resources](https://combogesic.com/resources/) **Published:** May 13, 2026 **Author:** damien **Content:** ## Resources [Clinical Studies](#clinicalstudies) [Educational Materials](#educationalmaterials) [Ordering Information](#orderinginfo) [Request Information](#requestinfo) ## Clinical Studies ### Effective. Fast. Multiple studies prove it. #### Efficacy and Safety Clinical Study Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial (Merry et al., 2010) Clinically proven in an acute pain study of post-operative relief after removal of 1-4 wisdom teeth. At maximum dosage, Combogesic® delivers at least 32% more effective pain relief than a full daily OTC dose of acetaminophen or ibuprofen alone. [View Study](https://academic.oup.com/bja/article/104/1/80/263593) #### Efficacy and Safety Clinical Study Analgesic Efficacy of an Acetaminophen/Ibuprofen Fixed‑dose Combination in Moderate to Severe Postoperative Dental Pain: A Randomized, Double‑blind, Parallel‑group, Placebo‑controlled Trial (Daniels et al., 2018) For patients undergoing extraction of 2-4 wisdom teeth, the fixed-dose acetaminophen + ibuprofen combination provided: - Significantly more effective pain relief than either acetaminophen or ibuprofen alone. - A faster onset of meaningful pain relief than acetaminophen or ibuprofen alone. - Reduction in the percentage of patients receiving opioids and their consumption of opioid rescue medication. [View Study](https://www.sciencedirect.com/science/article/pii/S0149291818303825) #### Pooled Safety Data An integrated safety analysis of combined acetaminophen and ibuprofen (Maxigesic®/Combogesic®) in adults (Aitken et al., 2019) This study pooled safety data for Combogesic® across four separate clinical trials showing that the incidence of adverse events experienced were similar to or below either acetaminophen, ibuprofen or placebo groups. Overall, Combogesic® is well tolerated and has a strong safety profile at single and multiple doses. [View Study](https://www.tandfonline.com/doi/full/10.2147/JPR.S189605) ## Educational Materials ### Tools to support your clinical decision making #### Prescribing Information Download the Prescribing Information for Combogesic® tablets [Download](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf) ### Ordering Combogesic® #### Combogesic® tablets purchasing information [Request samples](/hcp-qr/) [Access Combogesic](/how-to-access/) ## Request more information ### Contact us for any further information. [Contact us](https://combogesic.com/contact-us/) --- ### [Clinical Overview](https://combogesic.com/clinical-overview/) **Published:** May 13, 2026 **Author:** damien **Content:** # Clinical Overview ## The combination of acetaminophen and ibuprofen that’s more effective than either alone.2 ## *Powered by QS* [Overview](#overview) [Efficacy](#efficacy) [Safety](#safety) [Dosing](#dosing) [How to order](#howtoorder) ## Overview ### Non-opioid analgesia in a single formulation for acute pain management - Combogesic® is indicated in adults for the short-term management of mild to moderate acute pain.8 [Access Combogesic](/how-to-access/) ![](https://combogesic.com/wp-content/uploads/2026/05/Combogesic_bottle_tablets_clearcut-With-Shadows-With-No-TopSert-New-Cropped.png) ![](https://combogesic.com/wp-content/uploads/2026/05/combogesic_logo_footer.png)QikSolv™ is a patented breakthrough formulation developed in the US for rapid dissolution.3 ## The superior analgesic effect of Combogesic® tablets were shown over a 48-hour study period.2,\* ![](https://combogesic.com/wp-content/uploads/2026/06/icon_more_white.png)78% MORE EFFECTIVE pain relief than acetaminophen alone (P<0.001)2 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_more_white2.png)36% MORE EFFECTIVE pain relief than ibuprofen alone (P<0.001)2 ## Study design A key clinical study of post-operative pain relief over 48 hours after removal of 2-4 wisdom teeth shows that **Combogesic® provides more effective and a faster onset of meaningful pain relief** than the equivalent dose of acetaminophen or ibuprofen, given in 4 divided doses.2,8,\* Double blind study \[n=408\] 3 tablets, 4 times a day2 ### Placebo ### Acetaminophen (325 mg) 3900 mg/day ### Ibuprofen (97.5 mg) 1170 mg/day ### Combogesic® (325 mg + 97.5 mg) Acetaminophen **3900 mg/day** and Ibuprofen **1170 mg/day** Combogesic® was given every 6 hours over a 48-hour period, starting within 6 hours of surgery2,8,\* \*Self-reported pain intensity scores were recorded over a 48-hour double blind treatment period using a 100mm visual analogue scale. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over a 48-hour period (SPID48). ## Efficacy ![](https://combogesic.com/wp-content/uploads/2026/06/icon_more_effective.png)### Significantly more effective acute pain relief than either acetaminophen or ibuprofen alone2 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_prolonged.png)### Faster onset of meaningful acute pain relief than acetaminophen or ibuprofen alone2 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png)### Reduced need for opioid rescue medication2 [Explore the data](/resources/#clinicalstudies) ![](https://combogesic.com/wp-content/uploads/2026/06/icon_first_6hours.png) ## Combogesic® tablets provided **more effective pain relief in the first 6 hours than acetaminophen or ibuprofen alone**.2 FIRST **6 HRS** ## Significantly more effective pain relief in the first 6 hours vs acetaminophen & ibuprofen alone2 Combogesic® tablets delivered the lowest average pain scores within the first 6 hours, with a significant reduction in pain intensity observed 45 minutes after the first dose.2 [View study](/resources/#clinicalstudies) ![](https://combogesic.com/wp-content/uploads/2026/06/graph_mean_pain_intensity_score.png) ## Faster onset of meaningful pain relief than acetaminophen or ibuprofen alone2 Combogesic® tablets delivered meaningful pain relief approximately 6 minutes faster than acetaminophen and 19 minutes faster than ibuprofen alone.2 [View study](/resources/#clinicalstudies) ![](https://combogesic.com/wp-content/uploads/2026/06/graph_meaningful_pain_relief.png) ## Less opioid consumption (opioid-sparing effect)2 Combogesic® tablets minimized the need for opioid analgesia by delaying the time to first request, reducing the overall consumption, and limiting the number of patients who required opioid rescue medication.2 - The mean consumption of rescue medication (mg) in the **Combogesic® group (3.7 mg) was significantly lower** than the acetaminophen group (11.0 mg; P<0.001), ibuprofen group (7.1 mg; P=0.003), and placebo group (17.9 mg; P<0.001).2 - The number of participants requiring opioid rescue medication was significantly lower in the Combogesic® group compared to the other comparator groups (approx. 45% lower than ibuprofen, approx. 55% lower than acetaminophen).2 [View study](/resources/#clinicalstudies) ![](https://combogesic.com/wp-content/uploads/2026/06/graph_participants_requiring_rescue_medicaiton.png) ## Combogesic® is indicated in adults for the short-term management of mild to moderate pain.8 Advance your treatment plan for adult patients with acute pain. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_new_appraoach.png) ### New approach to multimodal analgesia Combogesic® tablets contain a combination of active compounds that target acute pain through different pathways that harness additive or synergistic effects to deliver a superior analgesic effect over either active ingredient used as single-modality interventions.9 [View guidelines](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf) ![](https://combogesic.com/wp-content/uploads/2026/06/icon_synergistic_combination.png) ### Synergistic combination Combogesic® tablets are a unique synergistic combination of **325 mg acetaminophen** and **97.5 mg ibuprofen** with no generic alternatives at the same optimized dosing. [View study](/resources/#clinicalstudies) ![](https://combogesic.com/wp-content/uploads/2026/06/icon_optimal_oral_dosing.png) ### Optimal oral dosing The convenient dosing regimen enables 3 Combogesic® tablets to be taken every 6 hours as needed for pain relief, up to a maximum of 12 tablets per day.8 [View package insert](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf) ## Safety ### Combogesic® is non-opioid. Non-habit forming. Just relief. #### Opioid sparing, non-addictive analgesia. Delays time to first request, reduces overall consumption and limits the number of patients who require opioid rescue medication.2 [Learn more](https://combogesic.com/resources/) #### Confirmed safety profile Combogesic® is well tolerated and has a strong safety profile at single and multiple doses. The incidence of adverse events was comparable to the individual components alone.2,10 Combogesic® enables the use of a lower dose of the NSAID component, thereby reducing the risk of adverse events typically associated with higher NSAID dosages or the use of more potent NSAIDs.10 [Learn more](https://combogesic.com/resources/) ## Dosing ### Recommended dosage for adult patients for mild to moderate acute pain ![](https://combogesic.com/wp-content/uploads/2026/05/Combogesic_bottle_tablets_clearcut-With-Shadows-With-No-TopSert-New-Cropped.png)Combogesic® tablets are approved for adults only (18 years and above). The dosing regimen is 3 tablets every 6 hours as needed for pain relief, up to a maximum of 12 tablets per day. Combogesic® tablets should be taken at the lowest effective dosage for the shortest duration, consistent with individual patient treatment goals, and should not be administered with other acetaminophen or NSAID-containing products.8 [View full dosage details](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf#page=3) ## How to Order ### Combogesic® tablets is available to order or sample at the links below. [Request samples](/hcp-qr/) [Access Combogesic](/how-to-access/) --- ### [Savings and Support](https://combogesic.com/patients/savings-and-support/) **Published:** May 29, 2026 **Author:** damien **Content:** # Savings and support ## Know what you’ll pay before you walk up to the counter ## The Problem ### The current system makes pricing needlessly hard. For millions of Americans, accessing brand-name and specialty pharmaceuticals can be a complex and costly challenge. But if you’re uninsured or on a high-deductible plan, you already know how quickly the cost of even everyday medications can add up. We believe no American should have to go without the medications they need. ## Our approach ### Combogesic® is built differently. Here’s what that means for you. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png) #### One transparent price A single, publicly posted cash price is what you pay — no hidden rebates, no markup, no surprises. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png) #### No insurance required Anyone can access Combogesic® at the same price, regardless of coverage status. Whether you’re insured, uninsured, or anywhere in between, you’re treated the same. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png) #### No waiting, no prior auth No formulary restrictions, no prior authorization delays, no step therapy requirements. You have a prescription — you get your medication. It’s that simple. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_reduced.png) #### No premiums, no deductibles You pay only when you purchase. No monthly premium, no deductible to satisfy before coverage kicks in. The cash price is the complete cost, every time. ### Experience simpler, more affordable pain relief Combogesic®. [Access Combogesic](/patients/how-to-access/) --- ### [Patient Resources](https://combogesic.com/patients/resources/) **Published:** May 29, 2026 **Author:** damien **Content:** ## Resources ## Clinical Studies ### Effective. Fast. Multiple studies prove it. #### Efficacy and Safety Clinical Study Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial (Merry et al., 2010) Clinically proven in an acute pain study of post-operative relief after removal of 1-4 wisdom teeth. At maximum dosage, Combogesic® delivers at least 32% more effective pain relief than a full daily OTC dose of acetaminophen or ibuprofen alone. [View Study](https://academic.oup.com/bja/article/104/1/80/263593) #### Efficacy and Safety Clinical Study Analgesic Efficacy of an Acetaminophen/Ibuprofen Fixed‑dose Combination in Moderate to Severe Postoperative Dental Pain: A Randomized, Double‑blind, Parallel‑group, Placebo‑controlled Trial (Daniels et al., 2018) For patients undergoing extraction of 2-4 wisdom teeth, the fixed-dose acetaminophen + ibuprofen combination provided: - Significantly more effective pain relief than either acetaminophen or ibuprofen alone. - A faster onset of meaningful pain relief than acetaminophen or ibuprofen alone. - Reduction in the percentage of patients receiving opioids and their consumption of opioid rescue medication. [View Study](https://www.sciencedirect.com/science/article/pii/S0149291818303825) #### Pooled Safety Data An integrated safety analysis of combined acetaminophen and ibuprofen (Maxigesic®/Combogesic®) in adults (Aitken et al., 2019) This study pooled safety data for Combogesic® across four separate clinical trials showing that the incidence of adverse events experienced were similar to or below either acetaminophen, ibuprofen or placebo groups. Overall, Combogesic® is well tolerated and has a strong safety profile at single and multiple doses. [View Study](https://www.tandfonline.com/doi/full/10.2147/JPR.S189605) ### Where to order Combogesic® Currently available at your local pharmacy and other stockists. [Access Combogesic](/patients/how-to-access/) ## Educational Materials ### Tools to support your clinical decision making #### Medication Guide Download the Medication Guide for Combogesic® tablets Download #### Prescribing Information Download the Prescribing Information for Combogesic® tablets [Download](https://www.aftpharm.com/us-en/wp-content/uploads/sites/7/2025/02/NDA-209471_PI_MI_AFT_dated-11.22.2024.pdf) ## Request more information ### Contact us for any further information. [Contact us](https://combogesic.com/patients/contact-us/) --- ### [FAQs](https://combogesic.com/faqs/) **Published:** May 13, 2026 **Author:** damien **Content:** ## FAQs ## FAQs for Combogesic® tablets ### What are Combogesic® tablets?+ Combogesic® tablets contain a fixed-dose combination of 325 mg acetaminophen and 97.5 mg ibuprofen per tablet. These two active ingredients work via distinct yet complementary mechanisms to provide more effective acute pain relief than equivalent doses of each individual active alone.2 Combogesic® offers a valuable option for the short-term management of mild to moderate acute pain in adults, with several key benefits. These include enhanced analgesic efficacy due to a synergistic action, simplified dosing through the combination of two agents in a single formulation, a well-established safety profile, and the potential to reduce reliance on opioids compared to monotherapy. ### How should Combogesic® tablets be taken?+ Combogesic® tablets are approved for adults only (18 years and above). The dosing regimen is 3 tablets every 6 hours as needed for pain relief, up to a maximum of 12 tablets per day. Combogesic® tablets should be taken at the lowest effective dosage for the shortest duration, consistent with individual patient treatment goals, and should not be administered with other acetaminophen or NSAID-containing products. ### Are there any circumstances in which Combogesic® tablets should not be taken?+ Combogesic® tablets are contraindicated in: - Patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product. - Patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. - The setting of coronary artery bypass graft (CABG) surgery Warning / Precaution is advised in those patients with: - Hypertension - Heart Failure and Edema - Renal Toxicity - Anaphylactic Reactions - Exacerbation of Asthma Related to Aspirin Sensitivity - Serious Skin Reactions - Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) - Fetal Toxicity - Hematologic Toxicity **HEPATOTOXICITY** COMBOGESIC contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product \[see Warnings and Precautions (5.1)\]. **CARDIOVASCULAR RISK** COMBOGESIC contains ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. \[see Warnings and Precautions (5.2)\]. COMBOGESIC is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery \[see Warnings and Precautions (5.2)\]. **GASTROINTESTINAL RISK** NSAIDS cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events \[see Warnings and Precautions (5.3) To find the full list of warning and contraindications please see full Prescribing Information including the boxed warning. ### Why do Combogesic® tablets contain 325 mg of acetaminophen and 97.5 mg of ibuprofen?+ Combogesic® is the only combination analgesic approved in the US containing acetaminophen and ibuprofen formulated in a 3.3:1 ratio, with multiple patents granted globally based on the synergistic effects demonstrated by this specific ratio. Clinical trials have confirmed that the patented 3.3:1 ratio used in Combogesic® delivers a synergistic combination that balances superior analgesic efficacy while minimizing the risk of adverse effects. Studies have also highlighted the importance of maintaining this precise ratio between acetaminophen and ibuprofen, when the ratio falls below this threshold, the synergistic interaction between the two agents diminishes, and a higher dose of ibuprofen relative to acetaminophen is required to attain the desired analgesic effect. ### Why is Combogesic® tablets different to taking acetaminophen & ibuprofen separately?+ The separate administration of acetaminophen and ibuprofen does not replicate the superior efficacy observed with Combogesic® with its unique 3.3:1 ratio. This is due to changes in the drug ratio during separate dosing, where an increased proportion of ibuprofen relative to acetaminophen diminishes the synergistic effect. Furthermore, a 2018 study evaluating alternating dosing of the individual components did not demonstrate a statistically significant improvement in pain scores. Therefore, taking alternating doses of each individual active ingredient does not deliver the synergistic benefits uniquely associated with Combogesic®. These findings highlight that co-administration of both agents simultaneously is advisable to achieve enhanced analgesic efficacy.11 ### Are Combogesic® tablets safe to take?+ Combogesic® is supported by a robust body of clinical data demonstrating its favorable safety profile. The postoperative safety profile of Combogesic® is comparable to that of acetaminophen and ibuprofen when used individually. By combining two active ingredients, Combogesic® enables the use of a lower dose of the NSAID component, thereby reducing the risk of adverse events typically associated with higher NSAID dosages or the use of more potent NSAIDs. Overall, Combogesic® is well tolerated and demonstrates a strong safety profile when administered as both single and multiple doses. ### What types of pain are Combogesic® tablets suited to treat?+ Combogesic® tablets are intended for adults who need short-term relief of mild to moderate acute pain. They combine acetaminophen and ibuprofen, two active ingredients that work in different ways, providing more effective pain relief than either medicine alone.2 Healthcare professionals may recommend Combogesic® for: - Common acute pain conditions. - Situations where a non-opioid option is preferred to reduce risks of dependence or certain adverse effects. - Patients who benefit from a multimodal approach, taking advantage of both medications together for consistent and reliable pain control. The dosing allows patients to manage pain effectively while staying within dosing limits for acetaminophen and ibuprofen. Its patented formulation is designed for consistent, dependable relief, offering an advantage over taking the two medicines separately. ### Have questions? [Contact us](https://combogesic.com/contact-us/) ### Start using Combogesic®. [Access Combogesic](/how-to-access/) --- ### [Why Combogesic®?](https://combogesic.com/why-combogesic/) **Published:** May 13, 2026 **Author:** damien **Content:** # Why Combogesic®? ## Giving your patients the relief they need matters. ## Non-Opioid matters. [The Problem](#theproblem) [How it works](#howitworks) [Clinical Rationale](#rationale) ## The Problem ### Ineffective pain relief has multiple impacts. ![](https://combogesic.com/wp-content/uploads/2026/06/icon_prolonged.png)#### Prolonged opioid use4 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_delayed.png)#### Delayed recovery time5 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_higher_heathcare_costs.png)#### Higher health-care costs6 ![](https://combogesic.com/wp-content/uploads/2026/06/icon_increased_hospital_readmissions.png)#### Increased hospital readmissions7 ![](https://combogesic.com/wp-content/uploads/2026/06/background1_flip.jpg)## Combogesic® is a unique non-opiod combination of acetaminophen and ibuprofen that’s more effective than either one alone.1,2 [Access Combogesic](/how-to-access/) ## How It Works ### Combogesic® tablets provide fast effective double action acute pain relief. ![](https://combogesic.com/wp-content/uploads/2026/05/combogesic_logo_footer.png)### Acetaminophen ### Ibuprofen ![](https://combogesic.com/wp-content/uploads/2026/06/Powered_by_QikSolv.png) QikSolv™ is a patented breakthrough formulation developed in the US for rapid dissolution.3 ### Two active medications working together Combogesic® offers health care providers a new approach to multimodal analgesia by combining two active medications with different mechanisms of action that work together to provide more acute pain relief than either medicine alone.1,2 ### How acetaminophen works Acetaminophen relives pain and reduces fever by acting mainly in the brain to help block pain signals, although its exact mechanism is not fully understood. ### How ibuprofen works Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that helps relieve pain and reduce inflammation by blocking certain enzymes involved in the body’s pain and inflammation response. ## A unique combination of acetaminophen and ibuprofen ### Optimized Dosing A fixed-dose oral combination (FDC) of **325 mg acetaminophen** and **97.5 mg ibuprofen** per tablet, offering up to 3900 mg acetaminophen and 1170 mg ibuprofen per day, bioequivalent to the recommended daily maximum of each individual active.8 ### Synergistic Ratio Clinical studies have demonstrated a synergistic effect when a unique **3.3:1 ratio** is used. As the ratio decreases (i.e. an increase of ibuprofen relative to acetaminophen) the apparent synergistic effect is weakened or lost.1,2 ### Multi-modal relief Evidence-based recommendations emphasize the importance of a multimodal approach to pain management using multiple interventions with different mechanisms of action that may offer additive or synergistic effects to optimize pain relief.9 --- ### [Privacy Policy](https://combogesic.com/privacy-policy/) **Published:** August 5, 2026 **Author:** damien **Content:** # Privacy Policy **This Privacy Policy is updated and effective as of November 5, 2024.** This website and any related mobile applications (collectively the “Website”) is operated by **AFT Pharmaceuticals US, Inc.** (referred to as “AFT”, “we”, “our” or “us”) for users who are residents of the United States. We have developed this Privacy Policy (the “Privacy Policy” or “Policy”) to inform you of the personal information we collect through the Website, what we do with your personal information, what we do to keep it secure, as well as the rights and choices you have over your personal information. ## **What Personal Information do we Collect and When?** The type of personal information that we will collect from you, and you voluntarily provide to us on this Website may include some or all of the following depending on the type of user you are: For businesses and individuals that visit and interact with our Website we collect the following types of information. | **Data Type** | **What We Collect and Store** | |---|---| | User-Generated Content/Data | Name, Email Address, Free Format Text (Subject and Message for “Contact us” submission) | | Website Usage Data | IP Address, Browser Type and Version, Operating System, Device Information (e.g., device type, screen resolution), Date and Time of Website Visits, Pages Visited on the Website, Clickstream Data (User’s navigational path) | | Cookies and Tracking Data | Cookies (e.g., session cookies, persistent cookies), User Tracking Information (for analytics and personalization) | ## **Why and How We Use Your Personal Information** **When you use our Website “Contact Us” submission form** When you make an inquiry on our Website using the “Contact Us” section, we will use your name, email address, phone number, and any other information provided to contact you about, and manage your inquiry. If your inquiry relates to an adverse reaction to any product, we will hold and manage your information in order to meet their legal requirements and may pass information to any relevant Regulators. **To Operate, Improve and Maintain our Business, Products, and Services** We use the personal information you provide to us to operate our business. For example, when you make a purchase, we use that information for accounting, audits, and other internal functions. We may use personal information about how you use our Website to enhance your user experience and to help us diagnose technical and service problems and administer our platform. **To Protect Our or Others’ Rights, Property, or Safety** We may also use personal information about how you use our Website and platform, to prevent, detect or investigate fraud, abuse, illegal use or violations of our Terms of Use, and to comply with court orders, governmental requests, or applicable law. ## **Using Your Personal Information: The Lawful Basis and Purposes** To process your personal information, we rely on certain lawful bases, depending on how you interact with our Website, platform, or services. If we do process your personal information, we may use one or more of the following lawful bases for processing: **As Necessary for Our Legitimate Interests or Those of Other Persons and Organizations, Including:** - For market research, analysis, and developing statistics - To ensure the security of our Website **As Necessary to Comply with a Legal Obligation, Including:** - When you exercise available rights under applicable law and make requests in accordance with such laws - For compliance with legal and regulatory requirements and related disclosures - For the establishment and defence of legal rights ## **Sharing of Your Personal Information** We do not sell your personal information. We may share your personal information with other organizations in the following circumstances: - We use data processors who are third parties who provide elements of services for us. We have Data Processing Agreements in place with our data processors. This means that they are not authorized to do anything with your personal information unless we have instructed them to do so. They are not authorized to share your personal information with any organization apart from us or further sub-processors authorized by us and who must also comply with our instructions concerning the handling of your personal information. They are required to handle and otherwise process your personal information securely and retain it for the period that we instruct. - AFT’s entities for the purposes and under the conditions outlined above. This includes its subsidiaries and other affiliated companies, including such affiliates located in New Zealand. Our Website contains links to websites owned and operated by third parties. If you use these links, you leave our Website. These links are provided for your information and convenience only and are not an endorsement by AFT of the content of such linked websites or third parties. AFT has no control over the contents of any linked website and is not responsible for such websites, their content or availability. ## **Cookies** We use cookies, which are small text files stored on your device. Using cookies is a way for us to make sure that our Website is continuously improved, meets your needs and can be used as a tool to optimize our business functions. For us to do this, we place functional cookies to make the Website function as well as other types of cookies that help us provide promotional information that we believe might be of interest to Website users. Some of these cookies track your use of our Website and visits to other websites and allow us to show you promotions for our products or services when you browse other websites. Please view our [**Cookie Policy**](https://www.aftpharm.com/us-en/cookie-policy/) for more information on our use of cookies. ## **Interest-Based Advertising** We may also participate in interest-based advertising, sometimes called online behavioral advertising. This means you may see advertising on our Website that is tailored to how you browse or interact with our Website, or you may see advertising for AFT and its products on other websites based on your browsing behavior across websites. Some of the websites where we advertise belong to ad networks that use your web browsing history to select which ads to display on their network websites; these ads may include advertising for AFT and our Website, but we do not share any personal information about you with those third-party ad networks. Other websites where you may see our ads, such as social media platforms, may use interest preferences that you have chosen on those sites, along with registration and other information about you, to select which ads to display to you. Some internet browsers, websites, and mobile devices offer opt-out mechanisms for interest-based advertising. Please refer to the website you are visiting, or your browser and device settings, for more information. You can also opt out of receiving interest-based ads from third parties who are members of the Network Advertising Initiative (NAI) or who follow the Digital Advertising Alliance’s Self-Regulatory Principles for Online Behavioral Advertising by visiting the opt-out pages on the [NAI website](http://www.networkadvertising.org/choices/) and the [DAA website](http://www.aboutads.info/choices/). ## **Third-Party Processors and Service Providers** Our third-party processors and service providers may process personal information about you on our behalf for the purposes described below: | **Service Type** | **Description** | |---|---| | **Service Type** | **Description** | | Security Vendors | These trusted experts employ advanced cybersecurity measures, such as intrusion detection, threat monitoring, and malware scanning, to help protect your personal information from unauthorized access and cyber threats. | | Customer Support Providers | We work with dedicated customer support providers. They assist in addressing your queries, resolving issues by securely managing and accessing relevant customer data. | | Content Delivery Networks (CDNs) | To optimize the speed and reliability of our online services, we rely on Content Delivery Networks (CDNs). CDNs efficiently deliver web content to you by strategically distributing it across global servers. Your data is cached and served from the nearest server, reducing latency, and enhancing your overall experience. | | Content Management Systems | To assist us in the creation, management, and design of our Website. | | Analytics and Advertising | To improve our products and provide you with relevant content and advertisements, we collaborate with analytics and advertising partners. They analyze user behavior, preferences, and demographics to personalize your experience and deliver targeted promotional messages. | | Hosting Services | Providing the facilities needed to create and maintain our Website, as well as make it accessible through the internet. | | **Specific Third Parties** | **Service Provided** | **Description of Service** | |---|---|---| | Podcom | IT infrastructure and development services | Podcom offers managed IT support and development services for AFT Group. | | Fastly | Content Delivery Network and Web protection services | Fastly offers web efficiency and protection services for our platform. | | P29 | Website Management and Administration | P29 offer website design and management services for our product. | | WordPress | Content Management | WordPress offers web content management systems. | ## **How Long We Keep Your Information** We will only retain your personal information for as long as necessary to fulfill the purposes we collected it for, including for the purposes of satisfying any legal, accounting, or reporting requirements. Where the same record must be kept by us for more than one purpose and there is a different retention period for each of those purposes, the record is kept for the longer period. To determine the appropriate retention period for personal information, we consider the amount, nature, and sensitivity of the personal information, the potential risk of harm from unauthorized use or disclosure of your personal information, the purposes for which we process your personal information and whether we can achieve those purposes through other means, and the applicable legal requirements. ## **Security** We have put in place appropriate security measures to help prevent your personal information from being accidentally lost, used, or accessed in an unauthorized way, altered, or disclosed. Platforms, systems, and facilities in which personal information are processed are protected by secure network architectures that contain firewalls and intrusion detection devices. In addition, we limit access to your personal information to those employees, agents, contractors, and other third parties who have a business need to know. They will only process your personal information on our instructions, and they are subject to a duty of confidentiality. ## **Contact Us** If you would like to exercise one of your rights as set out above, or if you have a question or a complaint about this Policy or the way that your personal information is processed, please contact us by one of the following means: Mail: 42714 Woodward Ave, Bloomfield Hills, MI 48304, Suite B Email: <customer.service@aftpharm.com> Phone: 01-248-631-4810 ## **Supplemental Terms for Residents of Certain States** **A. Your U.S. State Privacy Rights.** U.S. state consumer privacy laws provide residents of certain states additional rights regarding our use of their personal information. In particular, the following state-specific rights may be applicable to you: - California residents have the rights set forth in more detail in subsection C below of this Policy. - Residents of Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas, Utah, and Virginia residents have rights to: - Confirm whether we process their personal information. - Access and delete certain personal information. - Correct inaccuracies in their personal information, taking into account the information’s nature and the purpose of the processing (excluding Iowa and Utah). - Data portability. - Opt-out of personal data processing for: - targeted advertising (excluding Iowa); - sales; or - profiling in furtherance of decisions that produce legal consequences or other similarly significant effects (excluding Iowa and Utah). - Either limit (opt-out of) or require consent to process sensitive personal data. To exercise any of these rights please contact us as noted in the “Contact Us” portion of this Policy. **B. Appeals of Decisions Concerning Your Rights** For residents of California, Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas, Utah, and Virginia, to appeal any decision that we make with regard to your exercise of any of your aforementioned rights, please contact us as noted in the “Contact Us” portion of this Policy. **C. Your California Privacy Rights** The following additional privacy notices for California residents (the “**California Notice**”) supplement the information contained in the other portions of this Privacy Policy and apply solely to individuals who reside in the State of California (“**California consumer**” or “**you**”). The Company adopts this California Notice to comply with the California Consumer Privacy Act, as amended by the California Privacy Rights Act, and their related regulations (collectively the “**California Privacy Law**” or the “**CCPA**”) and other applicable California laws. ## **Overview of Consumer Rights Under the CCPA** Under the CCPA, California consumers have certain rights regarding their personal information, including: - The right to know the categories of personal information that we have collected and the categories of sources from which we obtained such information. - The right to know our business purposes for sharing personal information. - The right to know the categories of third parties with whom we shared personal information. - The right to know if we sold or disclosed your personal information for a business purpose, comprising two separate lists disclosing: - any sales, which list identifies the personal information categories that each category of recipient purchased (note that at present we do not sell personal information that we collect); and - any disclosures for a business purpose, which list identifies the personal information categories that each category of recipient obtained. - The right to access the specific pieces of personal information that we have collected - The right to correct personal information that we have collected. - The right to delete your personal information. - The right to not be discriminated against if you exercise your rights under the CCPA. The provisions below of this California Notice provide further details about these and other rights and certain details about the exercise of such rights. **Information We Collect** We collect information that identifies, relates to, describes, references, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular California consumer, household or device (collectively, “personal information”). Personal information does not include: - Publicly available information from government records. - De-identified or aggregated California consumer information. - Information excluded from the CCPA’s scope, including: - Health or medical information covered by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the California Confidentiality of Medical Information Act (CMIA) or clinical trial data; and - Personal information covered by certain other laws, including the Fair Credit Reporting Act (FCRA), the Gramm-Leach-Bliley Act (GLBA) or California Financial Information Privacy Act (FIPA), and the Driver’s Privacy Protection Act of 1994. We have collected the following categories of personal information from consumers within the last twelve (12) months: | **Category** | **Examples** | |---|---| | Identifiers | An individual’s name, alias, postal address, unique personal identifier, online identifier, Internet Protocol address, email address, account name, Social Security number, driver’s license number, passport number or other similar identifiers | | Personal information categories described in Cal. Civ. Code § 1798.80(e) | A name, signature, Social Security number, physical characteristics or description, address, telephone number, passport number, driver’s license or state identification card number, insurance policy number, education, employment, employment history, bank account number, credit card number, debit card number, or any other financial information, medical information, or health insurance information (Note: Certain of the above information may be considered to be sensitive personal information under the CCPA and, to the extent such data is considered to be sensitive personal information you have the right to limit the use and disclosure of such data.) | | Commercial information | Records of personal property, products or services purchased, obtained, or considered, or other purchasing or consuming histories or tendencies | | Internet or other similar network activity | Browsing history, search history, information on a California consumer’s interaction with our website, application, or advertisement and any social media sites from which user information is linked, connected or obtained | | Geolocation data | Physical location or movements (Note: Certain precise geolocation data may be considered to be sensitive personal information under the CCPA and, to the extent such data is considered to be sensitive personal information you have the right to limit the use and disclosure of such data.) | | Professional or employment-related information. | Current or past job history or performance evaluations. | | Non-public education information (per the Family Educational Rights and Privacy Act (20 U.S.C. Section 1232g, 34 C.F.R. Part 99)). | Education records directly related to a student maintained by an educational institution or party acting on its behalf, such as grades, transcripts, class lists, student schedules, student identification codes, student financial information, or student disciplinary records. | | Inferences drawn from other personal information | Examples include a person’s preferences, characteristics, psychological trends, predispositions, behavior, attitudes, intelligence, abilities and aptitudes | **Sources of Personal Information** In addition to sources of personal information addressed elsewhere in this Privacy Policy, we obtain the categories of personal information listed above from the following categories of sources: - **Directly From You.** For example, from forms you complete or products and services you purchase or from communications with you such as when you contact us (whether in person, by mail, by phone, online, via electronic communication or by other means) including our customer support service. - **Indirectly From You.** For example, from observing your actions on our website or from products or services that you have purchased from us, if you have enabled such functionality, such as telemetry services. - **From Others**. - From third party service providers. For example, if you choose to make an electronic payment directly to us, or through a linked website or mobile application, or through an affiliate of ours, we may receive personal information about you from third parties such as payment services providers, for the purposes of that payment. - From affiliates. We may collect personal information about you from our affiliates or others acting on their behalf. - **From Public Sources.** For example, we may collect information from public records. **Uses of Personal Information** In addition to uses of personal information addressed elsewhere in this Privacy Policy, we may use or disclose the personal information we collect for one or more of the following business purposes: - To fulfill the reason that you provided the information. For example, if you share your name and contact information to request a price quote, request to be contacted by an affiliate, or ask a question about our products or services, we will use that personal information to respond to your inquiry. If you provide your personal information to purchase a product or service, we may use that information to process your payment and facilitate delivery. We may also save your information to facilitate new product or service orders or to process returns. - To perform services such as customer service, order fulfillment, payment processing, financing and advertising, marketing or analytic services. - To advance our commercial or economic interests, such as by helping you to buy, rent, lease, join, subscribe to, provide, or exchange products, information, or services, or enabling or effecting, directly or indirectly, a commercial transaction. - To verify or maintain quality or safety standards or improve or upgrade a product or service provided or controlled by or for us. - To provide, support, personalize and develop our website, products and services such as to perform warranty related services or other post-sale activities such as product or service monitoring or repairs. - To create, maintain, customize and secure your account with us. - To process your requests, purchases, transactions and payments and prevent transactional fraud. - To provide you with support and to respond to your inquiries, including to investigate and address your concerns and monitor and improve our responses. - To personalize your website experience and to deliver content and product and service offerings relevant to your interests, including targeted offers and ads through our website, third-party sites and via mail, email or text message (with your consent, where required by law). - To help maintain the safety, security and integrity of our website, products and services, databases and other assets and business. - For testing, research and analysis purposes, including to develop and improve our website, products and services. - To respond to law enforcement requests and as required by applicable law, court order or governmental regulations. - As described to you when collecting your personal information or as otherwise set forth in the CCPA or applicable law. - To send you information relevant to your past purchases and interests, subject to compliance with applicable laws regarding direct marketing. - To otherwise use as reasonably necessary and proportionate to achieve our operational or notified purpose for collecting personal information and as compatible with the context in which we collected the information. - To perform services on behalf of a CCPA-covered business or its service provider, such as customer service, order fulfillment, payment processing, financing and advertising, marketing, or analytic services. - To review and audit our business interactions with you. - To detect or prevent security incidents or other illegal activity. - To evaluate or conduct a merger, divestiture, restructuring, reorganization, dissolution, or other sale or transfer of some or all of our assets, whether as a going concern or as part of a bankruptcy, liquidation, or similar proceeding, in which personal information held by us about our website users, including California consumers, is among the assets transferred. We will not collect additional categories of personal information or use the personal information we collected for materially different, unrelated or incompatible purposes without providing you notice. **Sharing Personal Information** We may disclose your personal information to a third party for a business purpose. When we disclose personal information for a business purpose, we enter a contract that describes the purpose and requires the recipient to both keep that personal information confidential and not use it for any purpose except performing the contract. In the preceding twelve (12) months, we have disclosed the following categories of personal information for a business purpose: - Identifiers - Personal information categories described in Cal. Civ. Code § 1798.80(e) - Commercial information - Internet or other similar network activity - Professional or employment-related information - Non-public education information - Inferences drawn from other personal information The categories of third parties to which we may disclose personal information collected by us include the following: - Service providers - Affiliates - Recipients of data from cookies **Sales of Personal Information** The Company does not sell personal information to third parties. **Exercising Your CCPA Rights and Choices** The sections below describe how you may exercise your rights under the CCPA. *Access to Specific Information and Data Portability Rights.* You have the right to request that we disclose certain information to you about our collection and use of your personal information. Once we receive and confirm your verifiable consumer request (see “Exercising Access, Data Portability and Deletion Rights” below), we will disclose to you: - The categories of personal information we collected about you. - The categories of sources for the personal information we collected about you. - Our business or commercial purpose for collecting that personal information. - The categories of third parties with whom we share that personal information. - The specific pieces of personal information we collected about you (also called a data portability request). - If we disclosed your personal information for a business purpose, a list disclosing the personal information categories that each category of recipient obtained. As allowed by the CCPA, we do not provide these access and data portability rights for business-to-business personal information. ***Deletion and Correction Request Rights.*** You have the right to request that we delete any of your personal information that we collected from you and retained, subject to certain exceptions. Once we receive and confirm your verifiable consumer request (see “Exercising Access, Data Portability, Deletion and Correction Rights” below), we will delete (and direct our service providers to delete) your personal information from our (and service provider) records, unless an exception applies. We may deny your deletion request if retaining the information is necessary for us or our service provider(s) to: - Complete the transaction for which we collected the personal information, provide a good or service that you requested, take actions reasonably anticipated within the context of our ongoing business relationship with you, fulfill the terms of a written warranty or product recall conducted in accordance with federal law, or otherwise perform our contract with you. - Detect security incidents, protect against malicious, deceptive, fraudulent, or illegal activity, or prosecute those responsible for such activities. - Debug products or services to identify and repair errors that impair existing intended functionality. - Exercise free speech, ensure the right of another California consumer to exercise their free speech rights, or exercise another right provided for by law. - Comply with the California Electronic Communications Privacy Act (Cal. Penal Code § 1546 et seq.). - Engage in public or peer-reviewed scientific, historical, or statistical research in the public interest that adheres to all other applicable ethics and privacy laws, when the information’s deletion may likely render impossible or seriously impair the research’s achievement, if you previously provided informed consent. - Enable solely internal uses that are reasonably aligned with California consumer expectations based on your relationship with us, such as future field campaigns or product safety issues. - Comply with a legal obligation. - Make other internal and lawful uses of that information that are compatible with the context in which you provided it. As allowed by the CCPA, we do not provide these deletion rights for business-to-business personal information. In addition, if you provide us with a verifiable consumer request to correct inaccurate personal information that we maintain about you, we will use commercially reasonable efforts to correct such information in accordance with your instructions. ***Exercising Access, Data Portability, Deletion and Correction Rights.*** To exercise the access, data portability, deletion and correction rights described above, you should submit a verifiable consumer request to us by using the contact information above under “Contact Information”. Only you, or someone legally authorized to act on your behalf, may make a verifiable consumer request related to your personal information. You may also make a verifiable consumer request on behalf of a minor child for whom you are a parent or legal guardian. You may only make a verifiable consumer request for access or data portability twice within a twelve (12) month period. The verifiable consumer request must provide sufficient information that allows us to reasonably verify that you are the person about whom we collected personal information or an authorized representative, which may include: - Your name - Your address - Additional information depending upon the type of request and the sensitivity of the information involved with such request - Describe your request with sufficient detail to enable us to properly understand, evaluate and respond to such request. We cannot respond to your request or provide you with personal information if we cannot verify your identity or your authority to make the request and confirm that the personal information involved with the request relates to you. Making a verifiable consumer request does not require you to create an account with us. However, we will consider requests made through a password-protected online account that you maintain with us to be sufficiently verified when the request relates to personal information associated with that online account, provided such online account functionality is then made available by us on the website. We will only use personal information provided in a verifiable consumer request to verify the requestor’s identity or authority to make the request. **Response Timing and Format** We endeavor to respond to a verifiable consumer request within forty-five (45) days of its receipt. If we require more time, we will inform you of the reason and extension period in writing. If you have an online account with us, we may deliver our written response to that online account, provided that such online account functionality is then made available by us on the website. If you do not have an online account with us, or such functionality is not available for your online account we will deliver our written response by mail or electronically, at your option. If we’re unable to comply with your request, the response we provide will also explain the reasons we cannot comply with the request. For data portability requests, we will select a format to provide your personal information that is readily usable and should allow you to transmit the information from one entity to another entity without hindrance. We do not charge a fee to process or respond to your verifiable consumer request unless it is excessive, repetitive or manifestly unfounded. If we determine that the request warrants a fee, we will tell you why we made that decision and provide you with a cost estimate before completing your request. **Non-Discrimination** We will not discriminate against you for exercising any of your CCPA rights. Unless permitted by the CCPA or other applicable law, we will not as a result of you exercising any of your rights under the CCPA: - Deny you goods or services; - Charge you different prices or rates for goods or services, including through granting discounts or other benefits, or imposing penalties; - Provide you a different level or quality of goods or services; or - Suggest that you may receive a different price or rate for goods or services or a different level or quality of goods or services. However, we may offer you certain financial incentives permitted by the CCPA that can result in different prices, rates, or quality levels. Any CCPA-permitted financial incentive we offer will reasonably relate to your personal information’s value and contain written terms that describe the program’s material aspects. Participation in a financial incentive program requires your prior opt in consent, which you may revoke at any time. **Retention of Personal Information** Our policy is to retain personal information only for as long as is necessary to fulfill the reason for which the personal information was collected and as necessary to process such personal information. In addition to the above, we will retain your personal information for the purposes of satisfying any professional, legal, accounting or reporting requirements to which we are subject. To determine the appropriate retention period for personal information, we consider the scope, nature and sensitivity of the personal information, the potential risk of harm from unauthorized use or disclosure of the personal information, the purposes for which we collected and processed your personal information and whether we can reasonably achieve those purposes through other means, as well as any applicable legal and professional requirements. **Other California Privacy-Related Disclosures** *Sharing Personal Information for Direct Marketing Purposes.* Before sharing personal information of California consumers with third parties for direct marketing purposes we will obtain opt-in consent from the applicable California consumers or provide such California consumers with a cost-free method to opt out. *California Do-Not-Track Disclosure.* At this time, the website is not set up to honor web browser do-not-track settings. Do-not-track is a privacy preference that users can set in their web browsers. When a user activates the do-not-track settings in browsers that offer this setting, the browser sends a message to websites or applications requesting them not to track the user. For more information about do-not-track matters, please visit www.allaboutdnt.org. *Information on Marketing Disclosures.* California Civil Code Section 1798.83 permits our users who are California residents to request and obtain from us once a year, free of charge, information about the personal information (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year. If applicable, this information would include a list of the categories of personal information that was shared and the names and addresses of all third parties with which we shared information in the immediately preceding calendar year. If you are a California resident and would like to make such a request, please submit your request in writing to us by using the contact information above under “Contact Information”. *Content Removal Requests for website Users Under 18 Years Old.* If you are a website user under 18 years of age and reside in California, you may request and obtain removal of, content or information that you have posted on the website. You may send us any such requests by one of the following methods: (i) by email (writing “Privacy Policy/Removal Request” in the subject line) or (ii) by postal mail by using the contact information above under “Contact Information”. We will review the request and respond promptly. You should be aware that a request to remove content or information posted by you on the website does not ensure or require complete or comprehensive removal of such content or information from our databases. **Complaints** If you have any complaint about use of the website, you may contact us by email or by postal mail by using the contact information above under “Contact Information”. In accordance with California Civil Code Section 1789.3, California residents may also file complaints with the Complaint Assistance Unit, Division of Consumer Services, California Department of Consumer Affairs by postal mail at 1625 North Market Road, Suite N112, Sacramento, CA 95834 or by telephone at 800-952-5210. **Changes to Our California Notice** We reserve the right to amend this California Notice at our discretion and at any time. When we make changes to this California Notice, we will post the updated California Notice on the website and update the California Notice’s effective date. Your continued use of our website following the posting of changes constitutes your acceptance of such changes. --- ### [HCP - QR](https://combogesic.com/hcp-qr/) **Published:** August 28, 2026 **Author:** Damien **Content:** ## Request Samples If you are interested in requesting Combogesic® samples, please use the form below to get in touch with us. Our team will reach out with more information. Please enable JavaScript in your browser to complete this form. Name \*First Last NPI# \* Address \*Address Line 1 Address Line 2 City — Select State\* —AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingState Zip Code Email Number Organization Phone Number \* Fax Number \* Email \* Organization \* Submit![Loading](https://combogesic.com/wp-content/plugins/wpforms/assets/images/submit-spin.svg) ## Report an Adverse Event To report an adverse event or product complaint, please contact us at <customer.service@aftpharm.com> or call 1-248-631-4810 or 1-800-962-8364. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch. Do not report adverse events through the email inquiry form. --- ### [Patents](https://combogesic.com/patents/) **Published:** May 13, 2026 **Author:** damien --- ### [Sitemap](https://combogesic.com/sitemap/) **Published:** May 13, 2026 **Author:** damien --- ### [Stockists](https://combogesic.com/patients/stockists/) **Published:** May 29, 2026 **Author:** damien **Content:** ## Stockists ## Find Combogesic® tablets [![](https://combogesic.com/wp-content/uploads/2026/06/Cost-Plus-Drugs-Marketplace-Logo.png)](https://www.costplusdrugs.com/) ### CostPlus [![](https://combogesic.com/wp-content/uploads/2026/06/TopRX-scaled.png)](https://toprx.com/) ### TopRX --- ### [Stockists](https://combogesic.com/stockists/) **Published:** May 27, 2026 **Author:** damien **Content:** ## Stockists ## Find Combogesic® tablets [![](https://combogesic.com/wp-content/uploads/2026/06/Cost-Plus-Drugs-Marketplace-Logo.png)](https://www.costplusdrugs.com/) ### CostPlus [![](https://combogesic.com/wp-content/uploads/2026/06/TopRX-scaled.png)](https://toprx.com/) ### TopRX --- ### [Disclaimer](https://combogesic.com/disclaimer/) **Published:** May 13, 2026 **Author:** damien **Content:** # Disclaimer Your access to and use of the information, content, materials, and services (collectively, the “Information”) made available on this website is governed by the Terms of Use Agreement located at [Terms of Use – AFT Pharmaceuticals USA](https://www.aftpharm.com/us-en/terms-of-use/), together with our Privacy Policy and this Disclaimer. **Please review the Terms of Use, the Privacy Policy, and this Disclaimer carefully before continuing to use the site.** By accessing or using the site, you acknowledge that you have read, understood, and agreed to be bound by each of these documents. As used in this Disclaimer, “United States” means the 50 states and the District of Columbia. The Information appearing on this site is published in summary form for the sole purpose of supporting your general awareness and understanding. It is **not intended to replace, and must not be relied upon as a replacement for**, the advice, diagnosis, or treatment recommendations of a licensed and qualified healthcare professional, nor as a substitute for formal medical training or instruction in any individual clinical scenario. The Information is made available **“AS IS” and “AS AVAILABLE,”** without any guarantee or assurance regarding its accuracy, reliability, currency, completeness, clinical applicability, or fitness for any particular use. **AFT PHARMACEUTICALS US, INC** TOGETHER WITH ITS PARENT COMPANIES, SUBSIDIARIES, AFFILIATED ENTITIES, AND THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AND AGENTS (COLLECTIVELY, “AFT PHARMACEUTICALS”), MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY, OR ARISING BY OPERATION OF LAW, COURSE OF DEALING, OR OTHERWISE, CONCERNING THE INFORMATION OR THIS WEBSITE. AFT PHARMACEUTICALS EXPRESSLY DISCLAIMS ALL SUCH REPRESENTATIONS AND WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, QUIET ENJOYMENT, TITLE, AND NON-INFRINGEMENT OF THIRD-PARTY RIGHTS. UNDER NO CIRCUMSTANCES SHALL AFT PHARMACEUTICALS BE HELD LIABLE FOR ANY LOSSES, INJURIES, OR DAMAGES OF ANY NATURE — INCLUDING WITHOUT LIMITATION DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES (SUCH AS LOST PROFITS, LOST REVENUE, LOST DATA, OR LOSS OF GOODWILL) — THAT ARISE OUT OF, RELATE TO, OR ARE OTHERWISE CONNECTED WITH YOUR ACCESS TO, USE OF, OR INABILITY TO USE THIS WEBSITE OR THE INFORMATION, REGARDLESS OF WHETHER **AFT PHARMACEUTICALS US, INC** HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND REGARDLESS OF THE LEGAL THEORY ASSERTED, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR OTHERWISE. Some jurisdictions do not permit the exclusion or limitation of certain warranties or liabilities. In such jurisdictions, the AFT Pharmaceuticals’ liability shall be limited to the maximum extent permitted by applicable law. This Disclaimer shall be governed by and construed in accordance with the laws of the State of Michigan, without regard to its conflict-of-laws principles. If any provision of this Disclaimer is found to be unenforceable or invalid, that provision shall be limited or eliminated to the minimum extent necessary so that the remainder of this Disclaimer remains in full force and effect. For questions regarding this Disclaimer, please contact: **AFT PHARMACEUTICALS USA, Inc.** Email: <customer.service@aftpharm.com> Phone: 01-248-631-4810 --- ### [Contact us](https://combogesic.com/patients/contact-us/) **Published:** May 29, 2026 **Author:** damien **Content:** ## Contact Us ## Email us If you would like to share your experience with using Combogesic®, please use the form below. We may be in touch to get more information about your story, but we will not share your story without asking you first. Please enable JavaScript in your browser to complete this form. Name \*First Last Phone Layout Name Email \* Phone Message \* Submit![Loading](https://combogesic.com/wp-content/plugins/wpforms/assets/images/submit-spin.svg) ## Report an Adverse Event To report an adverse event or product complaint, please contact us at <customer.service@aftpharm.com> or call 1-248-631-4810 or 1-800-962-8364. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch. Do not report adverse events through the email inquiry form. --- ### [Contact Us](https://combogesic.com/contact-us/) **Published:** May 13, 2026 **Author:** damien **Content:** ## Contact Us ## Email us **Health professionals and organizations:** If you have inquiries about Combogesic®, please use the form below to get in touch with us. Please enable JavaScript in your browser to complete this form. Name \*First Last Email \* Phone Job Title Organization \* Interested in \*— Select Choice —Requesting samplesContact a repFind out more Organization Message Name Message Submit![Loading](https://combogesic.com/wp-content/plugins/wpforms/assets/images/submit-spin.svg) ## Report an Adverse Event To report an adverse event or product complaint, please contact us at <customer.service@aftpharm.com> or call 1-248-631-4810 or 1-800-962-8364. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch. Do not report adverse events through the email inquiry form. --- ## News ### [From New Zealand to the World: The Global Growth Story of Combogesic®](https://combogesic.com/patient/news/from-new-zealand-to-the-world-the-global-growth-story-of-combogesic/) **Published:** July 24, 2026 **Author:** damien **Content:** Combogesic® was invented and developed in New Zealand by Dr. Hartley Atkinson, founder of AFT Pharmaceuticals. First introduced in New Zealand in 2009, this world-first specific combination analgesic, pairing acetaminophen and ibuprofen in a single fixed-dose formulation, has since become a cornerstone of AFT’s global product portfolio and is now sold in more than 60 countries around the world. ## **A Formulation Born from Unmet Clinical Need** Dr. Atkinson developed Combogesic to address a straightforward but important clinical question: could combining two of the most widely used and trusted over-the-counter analgesics into a single, precisely dosed product offer patients more effective, more convenient pain relief than either ingredient alone? That question shaped more than two decades of research and formulation work, and it continues to guide AFT’s ongoing investment in expanding the Combogesic platform including tablet, oral liquid, rapid-dissolving, and hospital-grade intravenous (IV) formulations designed for both consumer and clinical settings. ## **Steady, Disciplined International Expansion** What started in New Zealand has grown into a genuinely global brand. Combogesic (marketed as Maxigesic in many international markets) is now available in 87 countries spanning Australasia, Asia, Europe, North America, and Africa, supported by a network of AFT-operated business hubs and distribution partners. In the United States, AFT has been advancing both consumer-facing over-the-counter launches and Combogesic IV in partnership with Hikma Pharmaceuticals, alongside the broader rollout of Combogesic Rapid tablets. Momentum has followed in the United Kingdom, where Combogesic tablets are now distributed through more than 2,500 pharmacy locations and Combogesic IV continues to build formulary listings within the NHS system, and in Canada, where Combogesic IV has launched alongside a growing selected OTC offering. ---